期刊文献+

三才封髓汤加味治疗EGFR-TKI所致阴虚证36例临床观察 被引量:1

下载PDF
导出
摘要 目的:观察中药复方三才封髓汤加味治疗EGFR-TKI治疗后阴虚证的临床疗效。方法:采用区组随机、平行对照的方法,将接受EGFR-TKI治疗的晚期非小细胞肺癌患者分为治疗组和对照组各36例,治疗组用三才封髓汤加味内服,对照组用口泰含漱液、谷维素片等对症治疗。观察14天后两组整体疗效。结果:两组整体疗效有显著性差异(P<0.01)。结论:三才封髓汤加味对EGFR-TKI治疗后阴虚证有良好疗效。
出处 《浙江中医杂志》 2014年第1期30-31,共2页 Zhejiang Journal of Traditional Chinese Medicine
  • 相关文献

参考文献2

二级参考文献5

  • 1Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in t he epidermal growth actor receptor underlying responsiveness of nonsmall-cell lung cancer to Gefitinib. N Eng J Med, 2004,350 (21) : 2129-2139.
  • 2Han SW, Hwang PG, Chung DH, et al. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib in chemotherapy-resistant non small cell lung cancer. Int J Cancer, 2005,113 (i) :109-115.
  • 3Parra HS, Cavina R, Latteri F, et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (Iressa, ZD1839) in non-small-ceU lung cancer. Br J Canc- er, 2004,91 (2) :208-212.
  • 4Thomas J, Lynch Jr, Ed SKim, et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management. The Oncologist, 2007,12:610-621.
  • 5Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patient s wit h non-small-cell lung cancer treated wit h chemotherapy clone and in combination with erlotinib. J Clin Oncol,2005, 23 (4) :5900-5909.

共引文献56

同被引文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部